強直性脊椎炎および非X線性軸性脊椎関節炎を含む活動性軸性脊椎関節炎の被験者におけるビメキズマブの長期安全性、忍容性および有効性を評価する研究 (BE MOVING)
アクティブな軸性脊椎関節炎、強直性脊椎炎、および非 X 線撮影軸性脊椎関節炎の研究参加者の治療におけるビメキズマブの長期的な安全性、忍容性、および有効性を評価するための多施設非盲検継続研究
The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Arizona
-
Glendale、Arizona、アメリカ、85306
- As0014 50062
-
Phoenix、Arizona、アメリカ、85032
- As0014 50052
-
-
California
-
Upland、California、アメリカ、91786
- As0014 50060
-
-
Florida
-
Ormond Beach、Florida、アメリカ、32174
- As0014 50059
-
Sarasota、Florida、アメリカ、34239
- As0014 50056
-
-
Maryland
-
Hagerstown、Maryland、アメリカ、21740
- As0014 50015
-
-
Missouri
-
St Louis、Missouri、アメリカ、63141
- As0014 50016
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- As0014 50055
-
-
Pennsylvania
-
Duncansville、Pennsylvania、アメリカ、16635
- As0014 50020
-
-
Texas
-
Dallas、Texas、アメリカ、75231
- As0014 50057
-
-
-
-
-
Edinburgh、イギリス
- As0014 40057
-
Leeds、イギリス
- As0014 40056
-
Norwich、イギリス
- As0014 40055
-
-
-
-
-
Amsterdam、オランダ
- As0014 40034
-
-
-
-
-
A Coruña、スペイン
- As0014 40045
-
Córdoba、スペイン
- As0014 40046
-
Santiago de Compostela、スペイン
- As0014 40048
-
Seville、スペイン
- As0014 40049
-
-
-
-
-
Brno、チェコ
- As0014 40011
-
Pardubice、チェコ
- As0014 40009
-
Prague、チェコ
- As0014 40013
-
Prague、チェコ
- As0014 40014
-
Prague、チェコ
- As0014 40015
-
Prague、チェコ
- As0014 40016
-
Uherské Hradiště、チェコ
- As0014 40010
-
Zlín、チェコ
- As0014 40012
-
-
-
-
-
Ankara、トルコ(Türkiye)
- As0014 40052
-
Ankara、トルコ(Türkiye)
- As0014 40053
-
Istanbul、トルコ(Türkiye)
- As0014 40050
-
-
-
-
-
Berlin、ドイツ
- As0014 40025
-
Hamburg、ドイツ
- As0014 40029
-
Hanover、ドイツ
- As0014 40024
-
Herne、ドイツ
- As0014 40027
-
Leipzig、ドイツ
- As0014 40078
-
Ratingen、ドイツ
- As0014 40026
-
-
-
-
-
Debrecen、ハンガリー
- As0014 40032
-
Szeged、ハンガリー
- As0014 40031
-
Székesfehérvár、ハンガリー
- As0014 40033
-
-
-
-
-
Boulogne-Billancourt、フランス
- As0014 40018
-
Limoges、フランス
- As0014 40022
-
-
-
-
-
Plovdiv、ブルガリア
- As0014 40006
-
Plovdiv、ブルガリア
- As0014 40007
-
Sofia、ブルガリア
- As0014 40005
-
Sofia、ブルガリア
- As0014 40008
-
-
-
-
-
Brussels、ベルギー
- As0014 40004
-
Genk、ベルギー
- As0014 40003
-
Ghent、ベルギー
- As0014 40001
-
-
-
-
-
Elblag、ポーランド
- As0014 40038
-
Krakow、ポーランド
- As0014 40042
-
Lublin、ポーランド
- As0014 40037
-
Poznan、ポーランド
- As0014 40044
-
Torun、ポーランド
- As0014 40040
-
Warsaw、ポーランド
- As0014 40041
-
Wroclaw、ポーランド
- As0014 40039
-
Wroclaw、ポーランド
- As0014 40043
-
-
-
-
-
Beijing、中国
- As0014 20040
-
Chengdu、中国
- As0014 20021
-
Guangzhou、中国
- As0014 20019
-
Hefei、中国
- As0014 20034
-
Nanjing、中国
- As0014 20024
-
Shanghai、中国
- As0014 20018
-
Shanghai、中国
- As0014 20020
-
Shanghai、中国
- As0014 20026
-
Wenzhou、中国
- As0014 20025
-
-
-
-
-
Bunkyō City、日本
- As0014 20035
-
Chūōku、日本
- As0014 20030
-
Iruma-gun、日本
- As0014 20039
-
Kawachi-Nagano、日本
- As0014 20036
-
Kita-gun、日本
- As0014 20045
-
Kitakyushu、日本
- As0014 20065
-
Osaka、日本
- As0014 20037
-
Saga、日本
- As0014 20084
-
Saitama、日本
- As0014 20048
-
Sapporo、日本
- As0014 20031
-
Suita、日本
- As0014 20032
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Study participant is considered reliable and capable of adhering to the protocol (eg, able to understand and complete questionnaires), visit schedule, and medication intake according to the judgement of the Investigator
- In the opinion of the Investigator, the study participant is expected to benefit from participation in this extension study
- Study participant completed AS0010 (NCT03928704) or AS0011 (NCT03928743)
Exclusion Criteria:
- Female study participants who plan to become pregnant during the study or within 20 weeks following final dose of Investigational Medicinal Product (IMP). Male study participants who are planning a partner pregnancy during the study or within 20 weeks following the final dose
- Study participants who meet any withdrawal criteria in AS0010 or AS0011. For any study participant with an ongoing serious adverse event (SAE), or a history of serious infections (including hospitalizations) in the feeder study, the Medical Monitor must be consulted prior to the study participant's entry into AS0014
- Study participant has a positive or indeterminate interferon gamma release assay (IGRA) in AS0010 or AS0011, unless appropriately evaluated and treated
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Bimekizumab
Subjects will receive bimekizumab throughout the Treatment Period. |
Subjects will receive bimekizumab at prespecified time-points.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
時間枠:From Baseline (Day 1) until Safety Follow-Up (up to Week 180)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. |
From Baseline (Day 1) until Safety Follow-Up (up to Week 180)
|
|
Percentage of participants with serious adverse events (SAEs) during the study
時間枠:From Baseline (Day 1) until Safety Follow-Up (up to Week 180)
|
A serious adverse event (SAE) is any untoward medical occurrence that at any dose:
|
From Baseline (Day 1) until Safety Follow-Up (up to Week 180)
|
|
Percentage of participants with with treatment-emergent adverse Events (TEAEs) leading to withdrawal from the study
時間枠:From Baseline (Day 1) until Safety Follow-Up (up to Week 180)
|
Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment. |
From Baseline (Day 1) until Safety Follow-Up (up to Week 180)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 28
時間枠:Week 28
|
ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain. The domains are:
|
Week 28
|
|
Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 52
時間枠:Week 52
|
ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain. The domains are:
|
Week 52
|
|
Assessment of SpondyloArthritis International Society 40% response criteria (ASAS40) response at Week 112
時間枠:Week 112
|
ASAS40 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 40% improvement are defined as relative improvements of at least 40%, and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 domains and no worsening at all in the remaining domain. The domains are:
|
Week 112
|
|
Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 28
時間枠:Week 28
|
ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain. The domains are:
|
Week 28
|
|
Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 52
時間枠:Week 52
|
ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain. The domains are:
|
Week 52
|
|
Assessment of SpondyloArthritis International Society 20% response criteria (ASAS20) response at Week 112
時間枠:Week 112
|
ASAS20 will be calculated relative to Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743). The Assessment of SpondyloArthritis International Society (ASAS) criteria for 20% improvement are defined as relative improvements of at least 20%, and absolute improvement of at least 1 unit on a 0 to 10 Numeric Rating Scale (NRS) in at least 3 of the 4 following domains and absence of deterioration in the potential remaining domain. The domains are:
|
Week 112
|
|
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 28
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
|
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 52
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
|
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 112
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated self-reported instrument, which consists of six 10-unit horizontal Numeric Rating Scales (NRS) to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
|
Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 28
時間枠:Week 28
|
The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of <=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS40 domains. |
Week 28
|
|
Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 52
時間枠:Week 52
|
The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of <=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS domains. |
Week 52
|
|
Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) at Week 112
時間枠:Week 112
|
The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of <=2 units on a 0 to 10 unit scale in all 4 domains listed for ASAS domains. |
Week 112
|
|
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 28
時間枠:Week 28
|
The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below: 0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP [mg/L] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP. |
Week 28
|
|
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 52
時間枠:Week 52
|
The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below: 0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP [mg/L] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP. |
Week 52
|
|
Assessment of Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP) at Week 112
時間枠:Week 112
|
The ASDAS-C-Reactive Protein (ASDAS-CRP) consists of a number of assessments which are scored by the study participant and physician and multiplied by a proven formula as shown below: 0.121 x Total back pain (represented by the BASDAI Question 2 result) 0.058 x Duration of morning stiffness (represented by the BASDAI Question 6 result) 0.110 x PGADA 0.073 x Peripheral pain/swelling (represented by the BASDAI Question 3 result) 0.579 x (natural logarithm of the hs-CRP [mg/L] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue are all assessed on a numerical scale (0 to 10 units). The sum of these weighted components gives the ASDAS-CRP.+ 1) |
Week 112
|
|
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 28
時間枠:Week 28
|
The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS40 domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP). |
Week 28
|
|
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 52
時間枠:Week 52
|
The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP). |
Week 52
|
|
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 112
時間枠:Week 112
|
The Assessment of SpondyloArthritis International Society (ASAS) 5/6 response is defined as achieving at least 20% improvement in 5 of 6 domains, including the 4 domains defined for ASAS domains as well as spinal mobility (lateral spinal flexion) and high sensitivity C-reactive Protein (hs-CRP). |
Week 112
|
|
Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 28
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
|
Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 52
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
|
Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 112
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
The Bath Ankylosing Spondylitis Functional Index (BASFI) assesses physical function in comprising 10 items relating to activities during the past week. Each item ranges from 0 ('Easy') to 10 ('Impossible'). The BASFI is the mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating better physical function. A negative value in BASFI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
|
Change from Baseline in Nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 28
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
|
Change from Baseline in nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 52
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
|
Change from Baseline in Nocturnal Spinal Pain Numeric Rating Scale (NRS) at Week 112
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
Nocturnal spinal pain experienced by ankylosing spondylitis (AS) subjects is measured by one question: pain in the spine at night due to AS?. When responding, the subject is to consider the average amount of pain in the preceding week. It is assessed on a numerical scale (0 to 10 units). A lower score indicates less pain and an improvement of the outcome. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
|
Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 28
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
|
Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 52
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
|
Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 112
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
The Ankylosing Spondylitis Quality of Life (ASQoL), a validated disease-specific 18-item questionnaire, has been developed specifically for measuring health-related quality of life (HRQoL) in subjects with ankylosing spondylitis (AS) and has shown to be responsive in axial spondyloarthritis (axSpA). The ASQoL score ranges from 0 to 18 with a higher score indicating worse HRQoL. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
|
Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 28
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
|
Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 52
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
|
Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 28
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
|
Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 52
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the sum of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
|
Change from Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 112
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
The Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) characterizes the spinal mobility of subjects with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis (AS). It is a disease-specific measure consisting of 5 clinical measures to reflect subject axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 is calculated for each item based on the measurement. The mean of the sum of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the patient's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value the better the improvement. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
|
Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 28
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 28
|
|
Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 52
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 52
|
|
Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index at Week 112
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
The Maastricht Ankylosing Spondylitis Enthesitis (MASES) is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process) each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score indicates worsening. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
|
Change from Baseline in the Short Form 36-Item Health Survey (SF-36) physical component summary (PCS) at Week 112
時間枠:From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
There are 8 Short-Form 36-item Health Survey (SF-36) domain scores. In addition to domain scores, the Physical Component Summary (PCS) scores are calculated from the 8 domains. Each of the 8 domain scores and the component summary scores ranging from 0 to 100, with higher scores indicating better health status. A larger positive value in change from Baseline indicates an improvement. |
From Baseline of AS0010 (NCT03928704) or AS0011 (NCT03928743) to Week 112
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:UCB Cares、001 844 599 2273 (UCB)
出版物と役立つリンク
一般刊行物
- Brown MA, Rudwaleit M, van Gaalen FA, Haroon N, Gensler LS, Fleurinck C, Marten A, Massow U, de Peyrecave N, Vaux T, White K, Deodhar A, van der Horst-Bruinsma I. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Ann Rheum Dis. 2024 Nov 14;83(12):1722-1730. doi: 10.1136/ard-2024-225933.
- Mease PJ, Gensler LS, Orbai AM, Warren RB, Bajracharya R, Ink B, Marten A, Massow U, Shende V, Manente M, Peterson L, White K, Landewe R, Poddubnyy D. Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies. RMD Open. 2025 Apr 6;11(2):e005026. doi: 10.1136/rmdopen-2024-005026.
- Ramiro S, Poddubnyy D, Mease PJ, Lopez-Medina C, Kim M, Massow U, Taieb V, Kragstrup TW, McGonagle D. Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis. RMD Open. 2025 Oct 22;11(4):e005969. doi: 10.1136/rmdopen-2025-005969.
- Marzo-Ortega H, Navarro-Compan V, Dubreuil M, Mease PJ, Magrey M, Rudwaleit M, D'Agostino MA, Gaffney K, Kay J, de la Loge C, Massow U, Taieb V, Vaux T, Deodhar A. Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. RMD Open. 2025 Nov 28;11(4):e006013. doi: 10.1136/rmdopen-2025-006013.
- Mease PJ, Merola JF, Magrey M, Nash P, Poddubnyy D, Lebwohl M, Bajracharya R, Ink B, Marten A, Manente M, Peterson L, White K, Gensler LS. Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies. RMD Open. 2026 Mar 10;12(1):e006174. doi: 10.1136/rmdopen-2025-006174.
- Navarro-Compan V, Kiltz U, Mease PJ, Dubreuil M, Gaffney K, Deodhar A, de la Loge C, Prajapati C, Kavanagh S, Marzo-Ortega H. Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension. RMD Open. 2026 May 13;12(2):e006670. doi: 10.1136/rmdopen-2025-006670.
- Nikiphorou E, Tillett W, Deodhar A, Dubreuil M, Gossec L, Hwang M, Lubrano E, Machado PM, Rudwaleit M, de Wit M, Kavanagh S, de la Loge C, Ink B, Lambert J, Morup M, Boonen A, Walsh J. Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis. J Rheumatol. 2026 Aug 1:jrheum.2026-0104. doi: 10.3899/jrheum.2026-0104. Online ahead of print.
- Baraliakos X, Deodhar A, van der Heijde D, Van den Bosch F, Magrey M, Maksymowych WP, Tomita T, Xu H, Coarse J, Prajapati C, Manente M, Marten A, Gensler LS. Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results From 2 Phase III Studies. J Rheumatol. 2026 Aug 1:jrheum.2026-0113. doi: 10.3899/jrheum.2026-0113. Online ahead of print.
- Maksymowych WP, Ramiro S, Poddubnyy D, Baraliakos X, Lambert RGW, Massow U, Vaux T, Prajapati C, Marten A, de Peyrecave N, Ostergaard M. Impact of Dual Interleukin-17A and Interleukin-17F Inhibition With Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: Magnetic Resonance Imaging and Radiographic Outcomes From Two Phase 3 Studies and Their Open-Label Extension. Arthritis Rheumatol. 2026 Sep 14. doi: 10.1002/art.70336. Online ahead of print.
- Ramiro S, Proft F, Sengupta R, van Tubergen A, Molto A, Gensler LS, Kishimoto M, Taieb V, Kavanagh S, Evans S, Navarro-Compan V. Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years. Arthritis Res Ther. 2026 Jan 19;28(1):40. doi: 10.1186/s13075-026-03729-6.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- AS0014
- 2019-004163-47 (EudraCT番号)
- 2023-506527-28 (レジストリ識別子:EU Clinical Trials)
- U1111-1304-6865 (その他の識別子:World Health Organization (WHO))
- 2023 (米国 NIH グラント/契約)
- 2019 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD 共有時間枠
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD 共有アクセス基準
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。